Scholarlink

Background <p>Neuroblastoma, a highly malignant and heterogeneous tumor, is the most frequent extracranial solid malignancy in children.</p> Purpose <p>This study explores the prognostic significance and biological role of GAS6-AS1 in neuroblastoma, aiming to identify novel biomarkers that could enhance the understanding of disease progression.</p> Methods <p>RT-qPCR was used to measure GAS6-AS1 expression levels in neuroblastoma tissues. The association between GAS6-AS1 expression and clinical features was assessed using the chi-square test, while its prognostic impact was examined via Cox regression and Kaplan-Meier survival analysis. Functional experiments, including CCK-8, colony formation, and flow cytometry, were conducted to assess how GAS6-AS1 knockdown influences neuroblastoma cell proliferation and apoptosis. Additionally, Transwell assays evaluated its role in cell migration and invasion. Bioinformatics analysis and dual-luciferase reporter assays were employed to investigate downstream regulatory mechanisms.</p> Results <p>Elevated GAS6-AS1 expression was observed in neuroblastoma tissues and associated with adverse clinicopathological characteristics. Survival analysis revealed that high GAS6-AS1 levels independently predicted poorer outcomes. Functional assays revealed that GAS6-AS1 depletion attenuated oncogenic behaviors, including proliferation and metastatic potential. Further investigation identified miR-3200-3p as a downstream target of GAS6-AS1, where its suppression counteracted the inhibitory effects of GAS6-AS1 knockdown on malignant phenotypes. Moreover, the results of GO and KEGG analyses indicated that the involvement of the GAS6-AS1/miR-3200-3p axis in neuroblastoma progression may be related to protein polyubiquitination, MAP kinase activity, and autophagy.</p> Conclusions <p>This study establishes GAS6-AS1 as a promising prognostic biomarker in neuroblastoma. GAS6-AS1 exerts oncogenic effects by modulating miR-3200-3p, thereby promoting neuroblastoma progression through enhanced malignant phenotypes.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

LncRNA GAS6-AS1 enhances the progression of pediatric neuroblastoma by modulating miR-3200-3p

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年5月29日

查看全文
  • Jinwen Chen,
  • He Huang,
  • Junshan Lin,
  • Yali Xu,
  • Qiang Wu

摘要

Background

Neuroblastoma, a highly malignant and heterogeneous tumor, is the most frequent extracranial solid malignancy in children.

Purpose

This study explores the prognostic significance and biological role of GAS6-AS1 in neuroblastoma, aiming to identify novel biomarkers that could enhance the understanding of disease progression.

Methods

RT-qPCR was used to measure GAS6-AS1 expression levels in neuroblastoma tissues. The association between GAS6-AS1 expression and clinical features was assessed using the chi-square test, while its prognostic impact was examined via Cox regression and Kaplan-Meier survival analysis. Functional experiments, including CCK-8, colony formation, and flow cytometry, were conducted to assess how GAS6-AS1 knockdown influences neuroblastoma cell proliferation and apoptosis. Additionally, Transwell assays evaluated its role in cell migration and invasion. Bioinformatics analysis and dual-luciferase reporter assays were employed to investigate downstream regulatory mechanisms.

Results

Elevated GAS6-AS1 expression was observed in neuroblastoma tissues and associated with adverse clinicopathological characteristics. Survival analysis revealed that high GAS6-AS1 levels independently predicted poorer outcomes. Functional assays revealed that GAS6-AS1 depletion attenuated oncogenic behaviors, including proliferation and metastatic potential. Further investigation identified miR-3200-3p as a downstream target of GAS6-AS1, where its suppression counteracted the inhibitory effects of GAS6-AS1 knockdown on malignant phenotypes. Moreover, the results of GO and KEGG analyses indicated that the involvement of the GAS6-AS1/miR-3200-3p axis in neuroblastoma progression may be related to protein polyubiquitination, MAP kinase activity, and autophagy.

Conclusions

This study establishes GAS6-AS1 as a promising prognostic biomarker in neuroblastoma. GAS6-AS1 exerts oncogenic effects by modulating miR-3200-3p, thereby promoting neuroblastoma progression through enhanced malignant phenotypes.